|
Risk of myocardial infarction and stroke in smokers is related to plasma levels of inflammation-sensitive proteins.
Arterioscler Thromb Vasc Biol. 2004 Mar; 24(3):577-82. Epub 2004 Ene 15
Lind P, Engstrom G, Stavenow L, Janzon L, Lindgarde F, Hedblad B |
|
Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study.
Circulation.. 2004 Feb; 109(7):843-8. Epub 2004 Feb 2
Schwedhelm E, Bartling A, Lenzen H, Tsikas D, Maas R, Brummer J, Gutzki FM, Berger J, Frolich JC, Boger RH |
|
Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients.
Circulation. 2004 Feb; 109(7):867-73. Epub 2004 Feb 2
West NE, Ruygrok PN, Disco CM, Webster MW, Lindeboom WK, O´Neill WW, Mercado NF, Serruys PW |
|
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
Circulation. 2004 Feb; 109(7):837-42. Epub 2004 Feb 2
Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR. |
|
Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial a
Circulation. 2004 Feb; 109(7):874-80. Epub 2004 Feb 2
Sabatine MS, Morrow DA, Giugliano RP, Murphy SA, Demopoulos LA, DiBattiste PM, Weintraub WS, McCabe CH, Antman EM, Cannon CP, Braunwald E. |
|
Differential Treatment Benefit of Platelet Glycoprotein IIb/IIIa Inhibition With Percutaneous Coronary Intervention Versus Medical Therapy for Acute Coronary Syndromes: Exploration of Methods
Circulation. 2004 Feb; 109(5):641-6.
Pieper KS, Tsiatis AA, Davidian M, Hasselblad V, Kleiman NS, Boersma E, Chang WC, Griffin J, Armstrong PW, Califf RM, Harrington RA. |
|
Analysis of 1-Year Clinical Outcomes in the SIRIUS Trial: A Randomized Trial of a Sirolimus-Eluting Stent Versus a Standard Stent in Patients at High Risk for Coronary Restenosis
Circulation. 2004 Feb; 109(5):634-40.
Holmes DR Jr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong SC, Midei M, Snead D, Kuntz RE |
|
High Plasma Heparin Cofactor II Activity Is Associated With Reduced Incidence of In-Stent Restenosis After Percutaneous Coronary Intervention
Circulation. 2004 Feb; 109(4):481-6. Epub 2004 Ene 26
Takamori N, Azuma H, Kato M, Hashizume S, Aihara K, Akaike M, Tamura K, Matsumoto T |
|
Long-Term Antioxidant Intervention Improves Myocardial Microvascular Function in Experimental Hypertension
Hypertension. 2004 Feb; 43(2):493-8. Epub 2004 Ene 12
Rodriguez-Porcel M, Herrman J, Chade AR, Krier JD, Breen JF, Lerman A, Lerman LO |
|
Effect of dietary sodium intake on blood lipids: results from the DASH-sodium trial.
Hypertension. 2004 Feb; 43(2):393-8. Epub 2004 Ene 5
David W. Harsha, Frank M. Sacks, Eva Obarzanek, Laura P. Svetkey, Pao-Hwa Lin, George A. Bray, Mikel Aickin, Paul R. Conlin, Edgar R. Miller, III, and Lawrence J. Appel |
|
Increased Central Artery Stiffness in Impaired Glucose Metabolism and Type 2 Diabetes: The Hoorn Study
Hypertension. 2004 Feb; 43(2):176-81. Epub 2003 Dic 29
Miranda T. Schram, Ronald M.A Henry, Rob A.J.M van Dijk, Piet J. Kostense, Jacqueline M. Dekker, Giel Nijpels, Robert J. Heine, Lex M. Bouter, Nico Westerhof, and Coen D.A. Stehouwer |
|
Progression of Carotid Intima-Media Thickness and Plasma Antioxidants: The Los Angeles Atherosclerosis Study
Arterioscler Thromb Vasc Biol. 2004 Feb; 24(2):313-9. Epub 2003 Dic 1
James H. Dwyer, Maura J. Paul-Labrador, Jing Fan, Anne M. Shircore, C. Noel Bairey Merz, and Kathleen M. Dwyer |
|
Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial
Blood.. 2004 Feb; 103(3):927-33. Epub 2003 Oct 9
Jeanet M. Kemmeren, Ale Algra, Joost C. M. Meijers, Guido Tans, Bonno N. Bouma, Joyce Curvers, Jan Rosing, and Diederick E. Grobbee |
|
Serum Homocysteine in Relation to Mortality and Morbidity From Coronary Heart Disease: A 24-Year Follow-Up of the Population Study of Women in Gothenburg
Circulation. 2004 Feb; 109:601-606.
Zylberstein DE, Bengtsson C, Bjorkelund C, Landaas S, Sundh V, Thelle D, Lissner L |
|
Benefit of Clopidogrel Over Aspirin Is Amplified in Patients With a History of Ischemic Events
Stroke. 2004 Feb; 35(2):528-32. Epub 2004 Ene 22
Ringleb PA, Bhatt DL, Hirsch AT, Topol EJ, Hacke W; Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events Investigators |
|
Continuous 15-Year Decrease in Incidence and Mortality of Stroke in Finland: The FINSTROKE Study
Stroke. 2004 Feb; 35(2):420-5. Epub 2004 Ene 5
Juhani Sivenius, Jaakko Tuomilehto, Pirjo Immonen-Räihä, Minna Kaarisalo, Cinzia Sarti, Jorma Torppa, Kari Kuulasmaa, Markku Mähönen, Aapo Lehtonen, and Veikko Salomaa |
|
Genetic variability of von Willebrand factor and risk of coronary heart disease: the Rotterdam Study.
Br J Haematol. 2004 Feb; 124(3):343-7.
Van Der Meer IM, Brouwers GJ, Bulk S, Leebeek FW, Van Der Kuip DA, Hofman A, Witteman JC, Gomez Garcia EB |
|
Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin.
Br J Haematol. 2004 Feb; 124(3):348-354.
Khan T, Wynne H, Wood P, Torrance A, Hankey C, Avery P, Kesteven P, Kamali F. |
|
Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance.
Circulation. 2004 Ene; 109(2):166-71. Epub 2004 Ene 5
Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, Guyer KE, Tait AR, Bates ER |
|
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
N Engl J Med. 2004 Ene; 350(3):232-8.
Kastrati A, Mehilli J, Schuhlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Bollwein H, Volmer C, Gawaz M, Berger PB, Schomig A; Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators |
